Anticipate Dispensing Post-Exposure Prophylaxis for COVID-19

You'll hear buzz about casirivimab/imdevimab (Regen-COV), the first med authorized to PREVENT COVID-19 after exposure.

This monoclonal antibody is already authorized to TREAT certain outpatients 12 or older with COVID-19 who are at high risk for severe illness...such as those with diabetes, obesity, etc.

Now it may be used for COVID-19 prevention if these same high-risk patients are exposed to the virus...as "post-exposure prophylaxis."

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote